CYP2B6 and OPRM1 gene variations predict methadone-related deaths

Hannah Bunten, Wei-Jun Liang, Derrick Pounder, Collin Seneviratne, Michael David Osselton

    Research output: Contribution to journalArticle

    50 Citations (Scopus)

    Abstract

    The largest proportion of methadone-associated deaths occurs during the drug induction phase. We analysed methadone-related fatalities for gene variations linked with methadone action. A significant association between high methadone concentrations and the CYP2B6*6 allele characteristic of the slow metabolizer phenotype was identified. We suggest that the risk of methadone fatality may be predetermined in part by the CYP2B6*6 allele. A significant correlation was also observed between post-mortem benzodiazepine concentrations and the OPRM1 A118G allele GA in methadone-related fatalities. Screening for these susceptibility variations prior to methadone prescription could assist in reducing the potential for serious adverse effects.

    Original languageEnglish
    Pages (from-to)142-144
    Number of pages3
    JournalAddiction Biology
    Volume16
    Issue number1
    DOIs
    Publication statusPublished - Jan 2011

    Keywords

    • CYP2B6
    • fatalities
    • metabolism
    • methadone
    • OPRM1
    • pharmacogenomics
    • PLASMA-LEVELS
    • PHARMACOKINETICS
    • POLYMORPHISMS
    • GENOTYPES
    • CHANNEL

    Cite this

    Bunten, H., Liang, W-J., Pounder, D., Seneviratne, C., & Osselton, M. D. (2011). CYP2B6 and OPRM1 gene variations predict methadone-related deaths. Addiction Biology, 16(1), 142-144. https://doi.org/10.1111/j.1369-1600.2010.00274.x